Evidence map›Paper›PMID 40918738›Full record

ReviewBioactive materials2025

Nanotechnology strategies for endometrium health: Are we on the right track?

Victoria Herrara, Dana Tarab-Ravski, Subhash C Chauhan, Nikesh Narang, Mohammad Mirazul Islam, Dan Peer, Rajendra Prasad, Murali M Yallapu

Abstract readReview
In one paragraph

Review in Bioactive materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Is Emerging Nanomedicine a Friend or Foe to Germ Cells?International journal of nanomedicine · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Victoria HerraraDivision of Cancer Immunology and Microbiology, Medicine and Oncology Integrated Service Unit, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX, USA.
Dana Tarab-RavskiLaboratory of Precision Nanomedicine, Shmunis School of Biomedicine and Cancer Research, Tel Aviv University, Tel Aviv-Yafo, 69978, Israel.
Subhash C ChauhanDivision of Cancer Immunology and Microbiology, Medicine and Oncology Integrated Service Unit, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX, USA.
Nikesh NarangDepartment of Ophthalmology and Visual Sciences, University of New Mexico School of Medicine, Albuquerque, NM, USA.
Mohammad Mirazul IslamDepartment of Ophthalmology and Visual Sciences, University of New Mexico School of Medicine, Albuquerque, NM, USA.
Dan PeerLaboratory of Precision Nanomedicine, Shmunis School of Biomedicine and Cancer Research, Tel Aviv University, Tel Aviv-Yafo, 69978, Israel.
Rajendra PrasadSchool of Biochemical Engineering, Indian Institute of Technology (BHU)Varanasi, 221005, India.
Murali M YallapuDivision of Cancer Immunology and Microbiology, Medicine and Oncology Integrated Service Unit, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX, USA.

Funding

Rio Grande Valley Cancer Health Disparity Research CenterU54MD019970 · NIMHD · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI Deepu George · 2024 to 2026
$15.0M
Bridges to the Baccalaureate Research Training Program at The University of Texas Rio Grande ValleyT34GM137854 · NIGMS · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI CHEW, SUE ANNE, GALVEZ, GRISELDA LOPEZ · 2020 to 2024
$1.9M
Development of Targeted Nanotechnology Platform for Pancreatic CancerR01CA206069 · NCI · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI CHAUHAN, SUBHASH C. · 2016 to 2021
$1.7M
NCI NIH HHS R01 CA206069NIGMS NIH HHS T34 GM137854NIMHD NIH HHS U54 MD019970
6 · The paper itself

Abstract

The endometrium is a vital mucosal tissue which undergoes cyclical regeneration, differentiation, and remodeling upon hormonal, cellular, and molecular signaling networks. Dysregulation of these processes can trigger a range of pathological conditions including chronic inflammatory disorders, hyperplastic lesions, malignancies, and infertility, necessitating the need for effective therapeutic interventions. Furthermore, we are still dependent on conventional treatment modalities which are often constrained by inefficient drug biodistribution, systemic toxicity, and emergence of therapeutic resistance. Recently, nanomedicines have gained tremendous attention in human healthcare, because they not only diagnose the disease but also deliver therapeutic agents to the targeted site without affecting healthy organs. There are numerous nanotechnology-based approaches that have been applied for clinical usage(s). In addition, recent advances in nanoparticle-based photothermal therapy, immunomodulatory approaches, and molecular imaging techniques have demonstrated considerable potential in refining both therapeutic and diagnostic strategies for endometrial pathologies. Herein, we reviewed a comprehensive analysis of nanotechnology-driven innovations in endometrial disease management, elucidating their mechanistic foundations, translational prospects, and future trajectories in endometrium and gynecological nanomedicine.

Indexed as

Endometrial carcinomaEndometriosisEndometriumNanomedicineNanoparticles

Identifiers

PMID40918738
PMCPMC12410360

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.